Leading account and intent-based sales and marketing providers and technology solutions for the pharmaceutical industry: Introduction In the vast global landscape of the pharmaceutical industry,
The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with relapsed/refractory acute leukemia and a
Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That’s what a joint meeting of two FDA advisory committees will discuss on
The response from physician groups to President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. for HHS secretary has been rather measured so far. Take
Higher mean blood pressure (BP) levels were associated with faster rates of visual field progression in patients with glaucoma, according to a retrospective cohort study.
The inability of COVID vaccines to reach the long-lived plasma cell compartment in the bone marrow may explain their waning protection compared with vaccines for
Patients with metastatic urothelial carcinoma who achieved a complete response after more than 8.5 months of single-agent enfortumab vedotin (Padcev) were able to be off
Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare
This story is part of a series called “Ozempic: Weighing the Risks and Benefits.” It was produced in part through a grant from the NIHCM
WASHINGTON — Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10%